PURPOSE: Samarium-153 ((153)Sm) lexidronam is a bone-targeting radiopharmaceutical with a short physical half-life and a favorable toxicity profile. We evaluated the safety and feasibility of a concurrent combination of weekly docetaxel with repeated (153)Sm-lexidronam in patients with castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: A conventional 3 + 3 dose-escalation design was used for this study. Patients were treated in three cohorts comprising two cycles of weekly docetaxel at 25, 30, and 35 mg/m(2), respectively, on days 1, 8, and 15 of a 28-day cycle in combination with (153)Sm (1 mCi/kg) on day 1. Unacceptable hematologic toxicity (UHT) was defined as more than 7 days delay in therapy for inadequate counts: an absolute neutrophil count (ANC) more than 1,000/microL and platelets more than 70,000/microL were required at days 8 and 15 and ANC more than 1,500/microL and platelets more than 100,000/microL were required at cycle 2, day 1. If counts had not recovered by day 56 of either combination cycle, UHT was declared. RESULTS: Eighteen patients were treated in three cohorts. Two patients in separate cohorts experienced UHT; the maximum-tolerated dose for this regimen was not reached. The median interval between (153)Sm doses was 35 days (range, 27 to 57 days). The only significant toxicity was mild, transient myelosuppression. Five patients (28%) experienced grade 3 hematologic toxicity. There were no grade > or = 4 hematologic or nonhematologic toxicities. CONCLUSION: Two dosing cycles consisting of weekly docetaxel and monthly (153)Sm-lexidronam were well tolerated and feasible in this CRPC population.
PURPOSE:Samarium-153 ((153)Sm) lexidronam is a bone-targeting radiopharmaceutical with a short physical half-life and a favorable toxicity profile. We evaluated the safety and feasibility of a concurrent combination of weekly docetaxel with repeated (153)Sm-lexidronam in patients with castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: A conventional 3 + 3 dose-escalation design was used for this study. Patients were treated in three cohorts comprising two cycles of weekly docetaxel at 25, 30, and 35 mg/m(2), respectively, on days 1, 8, and 15 of a 28-day cycle in combination with (153)Sm (1 mCi/kg) on day 1. Unacceptable hematologic toxicity (UHT) was defined as more than 7 days delay in therapy for inadequate counts: an absolute neutrophil count (ANC) more than 1,000/microL and platelets more than 70,000/microL were required at days 8 and 15 and ANC more than 1,500/microL and platelets more than 100,000/microL were required at cycle 2, day 1. If counts had not recovered by day 56 of either combination cycle, UHT was declared. RESULTS: Eighteen patients were treated in three cohorts. Two patients in separate cohorts experienced UHT; the maximum-tolerated dose for this regimen was not reached. The median interval between (153)Sm doses was 35 days (range, 27 to 57 days). The only significant toxicity was mild, transient myelosuppression. Five patients (28%) experienced grade 3 hematologic toxicity. There were no grade > or = 4 hematologic or nonhematologic toxicities. CONCLUSION: Two dosing cycles consisting of weekly docetaxel and monthly (153)Sm-lexidronam were well tolerated and feasible in this CRPC population.
Authors: C Collins; J F Eary; G Donaldson; C Vernon; N E Bush; S Petersdorf; R B Livingston; E E Gordon; C R Chapman; F R Appelbaum Journal: J Nucl Med Date: 1993-11 Impact factor: 10.057
Authors: Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Oliver Sartor; Robert H Reid; Peter J Hoskin; Donald P Quick; Peter J Ell; Robert E Coleman; Jon A Kotler; Leonard M Freeman; Pierre Olivier Journal: Urology Date: 2004-05 Impact factor: 2.649
Authors: A T Porter; A J McEwan; J E Powe; R Reid; D G McGowan; H Lukka; J R Sathyanarayana; V N Yakemchuk; G M Thomas; L E Erlich Journal: Int J Radiat Oncol Biol Phys Date: 1993-04-02 Impact factor: 7.038
Authors: Joyce M van Dodewaard-de Jong; John M H de Klerk; Haiko J Bloemendal; Bart P J van Bezooijen; Marie J de Haas; Richard H Wilson; Joe M O'Sullivan Journal: Eur J Nucl Med Mol Imaging Date: 2011-07-27 Impact factor: 9.236
Authors: Jianqing Lin; Victoria J Sinibaldi; Michael A Carducci; Samuel Denmeade; Danny Song; Theodore Deweese; Mario A Eisenberger Journal: Urol Oncol Date: 2009-12-04 Impact factor: 3.498
Authors: Karen A Autio; Neeta Pandit-Taskar; Jorge A Carrasquillo; Ryan D Stephenson; Susan F Slovin; Dana E Rathkopf; Christina Hong; Glenn Heller; Howard I Scher; Steven M Larson; Michael J Morris Journal: Cancer Date: 2013-06-13 Impact factor: 6.860